BioCentury
ARTICLE | Clinical News

XLRS: Phase I/II data

September 19, 2016 7:00 AM UTC

Top-line data from 8 patients with XLRS in an open-label, U.S. Phase I/II trial showed that low- and mid-dose XLRS were generally well tolerated with mild to moderate ocular inflammation reported in t...